TrialBritish journal of cancer2024

Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).

Albert Font et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.